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Fibronectins (FNs) are high molecular weight glycoproteins present in extracellular 
connective tissue matrices (ECM) and extracellular fluids, including blood plasma. The 
human FN gene consists of 45 exons, and the primary mRNA transcripts are alternatively 
spliced to form up to 20 different mRNA variants (White et al., 2008). The FNs interact with 
other matrix proteins, such as collagens, glycosaminoglycans and fibrin, as well as cell 
surface receptors, including integrins α9β1, α5β1 and αvβ3, and Toll1like receptor 4 (TLR4) 
(Charo et al., 1990; Okamuraet al., 2001). The precise role of individual isoforms of FN in 
ECM biology and pathology remains unclear. One of the alternatively spliced exons encodes 
the extra domain A (EDA), also known as extra type III repeat, that is regulated 
developmentally and is found exclusively in cellular fibronectin (cFN) but not in plasma 
fibronectin (pFN) (Muro et al., 1999). The latter form is synthesized by hepatocytes and 
secreted into the circulation, while cFN is produced by a variety of cells, including 
fibroblasts and epithelial cells, and is deposited as fibrils in the ECM.
The in vivo role of the EDA variant has been studied by constructing mouse strains either 
constitutively expressing (FN-EDA+/+) or excluding it (FN-EDA−/−) (Muro et al., 2003). No 
embryonic lethality or postnatal malformations were observed in the case of the 
homozygous mutant FN-EDA−/− mice, suggesting that EDA is not required for normal 
development. However, significant abnormalities were observed in adult FN-EDA−/− 
animals. Specifically, the EDA peptide segment is not found in the skin of wild-type 
animals, but FN-EDA was shown to be essential for normal wound healing, particularly with 
respect to re1epithelization. While wound healing in EDA+/+ mice was indistinguishable 
from EDAwt/wt mice, the wounds in FN-EDA−/− mice showed ulcerations in the epidermis 
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resulting in delay of re1epithelialization. Furthermore, both FN-EDA+/+ and FN-EDA−/− 
mice had shortened lifespan compared to wild1type animals.
Compelling recent evidence has accumulated implicating a crucial role for FN-EDA not 
only in normal wound healing but also in fibroproliferative disorders characterized by 
increased production and deposition of ECM. Treatment of normal fibroblasts with TGF-β, a 
critical cytokine in the pathogenesis of a variety of fibroproliferative disorders, results in a 
substantial increase in FN-EDA production (Balza et al., 1988; Chalmers, 2011). 
Interestingly, FN-EDA up1 regulation precedes that of collagen, and FN-EDA is required 
for the induction of the myofibroblastic phenotype by TGF-β. Furthermore, FN-EDA null 
mice failed to develop significant lung fibrosis after bleomycin administration (Muro et al., 
2008). Recently, Varga and co-workers (Bhattacharyya et al., 2014) demonstrated increased 
FN-EDA in the skin and circulation of patients with scleroderma. Additionally, exogenous 
FN-EDA potently stimulated collagen production and myofibroblast differentiation in vitro 
which was mediated by TLR4. These observations stimulated our investigation of the role of 
FN-EDA in the development of keloids, an abnormal fibroproliferative response elicited by 
trauma to the skin of genetically susceptible individuals; the pathogenesis of this disorder 
remains obscure (Bran et al., 2009). Our results suggest that FN-EDA may play a critical 
role in the keloid disease process.
Discarded tissue specimens were obtained anonymously from patients undergoing cosmetic 
surgical excision of keloids and from patients undergoing panniculectomy (for patient 
information, see Supplementary Table S1). Use of discarded tissue was approved by the 
Institutional Review Board of Thomas Jefferson University. The tissues were dissected, 
sterilized with betadine solution, subcutaneous adipose tissue was removed, and the samples 
were prepared for gene expression analysis. Total RNA was extracted from all specimens 
using RNeasy Kit (Fibrous Tissue Kit, Qiagen, Alameda, CA) and reverse transcribed to 
cDNA. Primer pairs were designed to amplify FN-EDA gene sequences as well as the 
housekeeping gene, glyceraldehyde-3-phosphodehydrogenase (GAPDH) as a control (for 
primer sequence information, see Supplementary Table S2). Relative quantitative RT-PCR 
was performed to investigate the expression of total FN as well as FN-EDA in both keloid 
and control specimens. As demonstrated previously (Kischer and Hendrix, 1983; Sible et al., 
1994), the total FN expression was increased in keloids by 10.7-fold over controls. 
However, the results indicated a dramatic, up to 70-fold (p = 0.005851) increase in FN1EDA 
mRNA in keloid tissues in comparison to controls (n = 5 both groups; Fig. 1a). Thus, the 
relative increase in cFN-EDA in comparison to total FN was ~7-fold higher in keloids.
To investigate whether the increased mRNA transcript levels result in similarly increased 
protein levels in keloid tissues, total protein was extracted from five keloids and control 
tissue specimens via bead-mill homogenization in the presence of protein lysis buffer 
containing RIPA buffer, PMSF, and EDTA-free protease inhibitor cocktail (Roche 
Diagnostics, Indianapolis, IN) . Twenty μg of total protein from each sample was subjected 
to SDS/PAGE (4-20% gel) in the presence of reducing agent. Protein was electrotransferred 
to polyvinylidene fluoride membrane, and nonspecific binding sites on the membrane were 
blocked by incubation in 5% milk for 1 hour at room temperature. The blot was incubated 
with anti-fibronectin EDA antibody (IST-9) at 1:200 dilution overnight at 4°C and anti-β 
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actin primary antibody (ab8224, Abcam, Cambridge, MA), and then incubated with Licor 
800cw infrared anti-mouse secondary antibody at 1:5,000 dilution for 1 hour at room 
temperature. After several washings, the signal was determined with Odyssey infrared image 
scanner (LiCor Biotechnology, Lincoln, NE).
Western blotting of the protein from keloids, as illustrated in Fig. 1b, revealed a significantly 
enhanced level of FN-EDA of the molecular weight of ~220 kDa, corresponding to a FN 
monomer, while very little, if any, protein was found in extracts of control specimens. 
Localization of FN-EDA in keloid tissues was determined by immunofluorescence staining 
with the same antibody (IST-9 monoclonal hybridoma supernatant, undiluted) as used for 
Western blotting, recognizing a 10-amino acid peptide sequence within the EDA segment, 
and an antibody to type III collagen (Rockland No. 600-401-105-0.1), overnight at 4°C 
followed by 3 washes in phosphate buffered saline (PBS). Sections were incubated for 1 
hour at room temperature with 1:200 dilutions in PBS of Alexa Fluor 488 goat anti-mouse 
and Alexa Fluor 594 goat anti-rabbit secondary antibodies (Invitrogen). After 3 washes in 
PBS, sections were then incubated at room temperature for 15 minutes with a 1:1,000 
dilution of DAPI in PBS (Southern Biotech). After washing 3X with PBS, sections were 
mounted in Fluoromount G (Southern Biotech) and visualized. The results indicated intense 
staining of FN-EDA in association with broad collagen fibers within the keloids, as 
visualized by anti-type III collagen antibody, while little, if any, staining was noted in 
control skin (Fig. 1c, d). Thus, the keloidal lesions contain an abundance of FN-EDA.
While total FN expression has been shown to be higher in keloid fibroblasts compared to 
control dermal fibroblasts (Kischer and Hendrix, 1983; Sible et al., 1994), the high level of 
FN-EDA expression in keloid tissue has not been previously reported. Although the 
mechanisms of the high level of FN1EDA expression in keloid tissue and its virtual absence 
in normal tissue remains to be determined, its presence may explain in part the continuous 
excess matrix production. EDA acting through the TLR4 receptor may enhance the 
activation of fibroblasts resulting in increased production of TGF1β and subsequent 
production and accumulation of ECM molecules, particularly collagen, creating a positive 
feedback loop, thus establishing progressive fibrosis. This hypothesis suggests that blocking 
FN-EDA synthesis or its interactions with cell surface receptors may provide suitable 
strategies to interrupt the fibrotic reaction in keloids.
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Abbreviations
FN fibronectin
EDA extra domain A
ECM extracellular matrix
TLR4 toll-like receptor 4
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Figure 1. 
Expression of FN-EDA in keloid tissues (a). Note 70-fold increase in mRNA levels in keloid 
tissue versus control (n = 5 for both groups; mean ± SE; p = 0.005851). Western blot results 
for tissue protein isolates from three keloid samples and three control samples (b). A total of 
20μg protein was loaded into each well; presence of fibronectin1EDA (220 kD) is 
demonstrated in keloid extracts versus near total absence in controls. Positive control (β-
actin) is present in each protein isolate (42 kD). Immunofluorescence of frozen sections of 
keloid (1c, left and 1d; scale bar = 30 μm) and control skin (1c, right). Note the heavy 
decoration of the surfaces of the type III collagen fibers (shown in red) with FN-EDA 
antibody (shown in green), in keloids in contrast to complete absence of FN-EDA in control 
skin (1c, right).
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